Brazil Court Suspends Sigma Lithium Mine Operations 
Novartis M&A Strategy Faces Investor Scrutiny After Drug Setbacks 
AstraZeneca Q2 Earnings Beat Forecasts as Oncology Growth Supports 2026 Outlook 
U.S. Stock Futures Steady as Oil Tops $100 Ahead of Inflation Data 
Zara Owner Inditex Sales Rise 9% in August 
UK Economy Grows 0.4% in July, Beating Forecasts 
US Judge Dismisses Gautam Adani Criminal Charges 
White House Seeks $1.4 Billion to Combat Growing Ebola Outbreak 
German Inflation Accelerates to 2.9% in August 
Nvidia Plans 2GW Australia AI Data Center Expansion by 2027 
BOJ Set to Raise Rates to 1.25% as Inflation Risks Build 
Oil Prices Hold Near Highs as U.S.-Iran Conflict Escalates 
Longsys Raises $903 Million in Hong Kong IPO as Shares Debut Flat 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
Blackstone Eyes $2 Billion ZO Skin Health Sale 
Iraq Seeks 6 Million Bpd OPEC+ Oil Quota 
Add as a preferred source on Google
The Seoul Central District Court had ruled that Medytox's patents for botulinum toxin (botox) strains and manufacturing process were stolen by Daewoong Pharmaceutical in developing Nabota.
Thus, the court prohibited Daewoong from manufacturing and selling its botox products, ordering that those that have already been produced should be discarded.
It also ordered Daewoong to pay 40 billion won in damages to Medytox, the first Korean company to succeed in mass-producing botox strains.
Medytox sued Daewoong in 2017, accusing it of stealing its botox strain and manufacturing process.
Daewoong claimed that it found its botox strain in a barn in Gyeonggi Province.
Medytox vowed to continue to protect its patent, while Daewoong said it would appeal the ruling.
The US International Trade Commission (USITC) had earlier ruled in favor of Medytox in December 2020 and ordered a 21-month import ban on Daewoong's products into the US. Daewoong also agreed to pay royalties to Medytox to settle the dispute shortly after the USITC decision.
